Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13822288 | 0.78 | KDR (0.68) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL31465342 | 0.75 | PLK4 (0.46) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL2284618 | 0.72 | PRKAB2 (0.65) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL3754835 | 0.71 | PRKAB2 (0.54) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL31487543 | 0.70 | PLK4 (0.47) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL12517742 | 0.69 | PRKAB2 (0.49) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL2281774 | 0.68 | PRKAB2 (0.51) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL31509364 | 0.67 | PLK4 (0.47) | PLK4AURKADYRK3MAP4K4NTRK1 | |
| SCHEMBL12517722 | 0.67 | MARK3 (0.42) | NTRK1CDK2MARK3KDRFLT3 | |
| SCHEMBL2810629 | 0.65 | KDR (1.00) | PLK4AURKADYRK3MAP4K4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523552-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2523552-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8946237-B2 | Pyrazolo[1,5-A]pyrimidines as mark inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946237-B2 | Pyrazolo[1,5-A]pyrimidines as mark inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946237-B2 | Pyrazolo[1,5-A]pyrimidines as mark inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130210838-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210838-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210838-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| EP-2523552-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011087999-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011087999-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210838-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS | MARK3, MARK4, MARK1 | PLK4 242/4885AURKA 18/4885DYRK3 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.